Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Generic Drug Office Goes On Diet Before Swallowing User Fees

Executive Summary

Congress sets $52.9 million floor for Office of Generic Drugs in FY 2012, less than in 2011, as part of $3.8 billion FDA funding package. Overall, FDA gets a $50 million boost, but sequestration looms. Appropriations conferees enter the user fee debate, asking how fast FDA approves drug applications.

You may also be interested in...



FDA Considers Cuts And Initiatives For Fiscal 2014 – Hamburg

Commissioner Hamburg tells FDA’s Science Board that in the early stages, both cuts and expansions are on the table as the budget process begins in preparation for the fiscal year starting October 2013.

FDA Considers Cuts And Initiatives For Fiscal 2014 – Hamburg

Commissioner Hamburg tells FDA’s Science Board that in the early stages, both cuts and expansions are on the table as the budget process begins in preparation for the fiscal year starting October 2013.

FDA Facing Possible Cuts – Or New Initiatives – In FY 2014 Budget, Hamburg Says

Commissioner tells agency science board that both are on the table as the budget process begins in preparation for the fiscal year that begins in October 2013.

Related Content

Topics

UsernamePublicRestriction

Register

PS053981

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel